Prescriptions for Ozempic soar

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

Forbes on MSN · 2h

Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low

Investors’ have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight loss drug makers Eli Lilly (shares up 60%) and Novo Nordisk (shares up 50%).

The Financial Times · 3h

Pfizer drops plan for twice-daily obesity pill due to side effects

Pfizer is abandoning its plans for a weight loss pill to be taken twice a day after trials showed it caused significant side effects, in a setback to the US drugmaker’s effort to enter the fast-growing market for obesity treatments.

CNBC · 4h

Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.

Houston Chronicle · 43m

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. The pharmaceutical company said it will focus instead on a once-daily version of the pill,

MarketWatch on MSN · 5h

Pfizer’s stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation

MARKET PULSE Pfizer Inc.’s stock fell 4% premarket Friday, after the company said it’s not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adults with obesity and type 2 diabetes after high rates of adverse events in the Phase 2b trial.

Reuters16h

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...

3mon

Wegovy weight-loss drugmaker sees profits soar

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

Healthline15d

Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy

Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 ...

Yahoo1mon

These 15 metro areas saw biggest jumps in Ozempic use. They might not be where you expect.

A diabetes medication in short supply for the last two years often was prescribed to people who didn't have the disease, and prescribing rates varied dramatically across the country, new data shows.

The Motley Fool28d

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's. Both stocks could be winners for ...

Futurism1mon

Snack Food CEO Vows to Battle Ozempic

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Benefits Pro3d

Grappling with weight loss drug coverage? Options to help employers control costs

Instead of jumping to GLP-1 drugs that can be costly, a step therapy approach guides patients by offering individualized care ...

Hosted on MSN1mon

Fake Ozempic pens circulating in Europe, watchdogs warn

Fake injection pens of Ozempic, a hugely popular diabetes drug that went viral on social media as a way to lose weight, are circulating in Europe, drug authorities have warned. Ozempic, which ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending on Bing